TNXP — Tonix Pharmaceuticals Holding Share News
0.000.00%
Last trade - 00:00- $88.67m
- -$87.56m
- $13.11m
US FDA approves Tonix Pharma's drug to manage pain related to chronic condition
Tonix Pharmaceuticals Holding Corp reports results for the quarter ended June 30 - Earnings Summary
Tonix Pharmaceuticals Holding Corp expected to post a loss of $3.24 a share - Earnings Preview
Tonix Pharmaceuticals reports Q2 net loss of $28.3 mln
Brief: Tonix Pharmaceuticals Holding May Sell Up To $150 Million In Common Stock
Brief: Tonix Pharmaceuticals Announces First Patient Dosed In Phase 2 Oasis Study Of TNX-102 SL For Reduction Of Acute Stress Reaction
Brief: Tonix Pharmaceuticals Announces Appointment Of Joseph Hand, Esq., As General Counsel And Executive Vice President Of Operations
Tonix Pharmaceuticals Holding Corp reports results for the quarter ended March 31 - Earnings Summary
Tonix Pharmaceuticals Holding Corp expected to post a loss of $3.23 a share - Earnings Preview
Brief: Tonix Pharmaceuticals Holding Corp - Discontinued Enrollment And Terminated Phase 2 Catalyst Study - SEC Filing
Brief: Tonix Pharmaceuticals Presented Data On Potential Mpox Vaccine TNX-801 At World Vaccine Congress Washington 2025
Brief: Tonix Pharmaceuticals Announces Oral Presentation And Panel Participation At The World Vaccine Congress Washington 2025
Brief: Tonix Pharmaceuticals And Makana Therapeutics Announce Collaboration Combining Tonix’S Anti-Cd40l Monoclonal Antibody (Tnx-1500) With Makana’S Genetically Engineered Organs In Preclinical And Clinical Xenotransplantation Studies
Brief: Tonix Pharmaceuticals receives MCDC grant for devloping its single-dose Mpox and Smallpox vaccine
U.S. STOCKS ON THE MOVE-Talen Energy, Gold miners, Stratasys
Brief: Tonix Pharmaceuticals Expects Topline Data For Tnx-1300 In Q3 2025, TNX-1500 In Q1 2025
Brief: Tonix Pharmaceuticals Holding Corp - Increases Maximum Aggregate Offering Price To $250 Million
Brief: Tonix Pharmaceuticals Announces Peer-Reviewed Publication In Msphere Journal Highlighting The Tolerability Of Company’S Single-Dose Mpox And Smallpox Vaccine Candidate TNX-801, In Immune-Compromised Animals
Tonix Pharmaceuticals Holding Corp reports results for the quarter ended September 30 - Earnings Summary